Two Studies Confirm Overall Survival Benefit of CDK 4/6 Inhibitors in Breast Cancer

Rodrigo Arrangoiz MS, MD, FACS, FSSO

img_3754

  • Two studies reported at the European Society of Medical Oncology (ESMO) Congress 2019:
    • Have shown that use of a CDK 4/6 inhibitor plus fulvestrant:
      • Can significantly improve the survival of women with hormone receptor-positive (HR-positive), HER2-negative advanced breast cancer.
  • Data from the phase 3 MONARCH-2 study:
    • Showed that abemaciclib plus fulvestrant:
      • Provided a significant 9.4-month overall survival improvement in pre- or perimenopausal women and postmenopausal women with hormone receptor positive (HR-positive), HER2-negative advanced breast cancer who had failed on endocrine therapy.
  • Data from the phase 3 MONALEESA-3 trial:
    • Showed that ribociclib plus fulvestrant:
      • As first-line or second-line treatment:
        • Demonstrated a statistically significant improvement in overall survival among postmenopausal women with HR-positive, HER2- negative advanced breast cancer.
  • Both studies showed an improvement in overall survival:
    • Which implies that patients receiving these drugs live longer than patients taking endocrine therapy alone – Rodrigo Arrangoiz MD, MS, FACS
  • After the announcement of these trial results:
    • We now have four trials that have each showed improved survival in metastatic estrogen receptor positive breast cancer for patients who take a CDK 4/6 inhibitor along with endocrine therapy (in 3 of the 4 trials the endocrine therapy was fulvestrant) – Dr. Arrangoiz.
    • Three of these trials have reached statistical significance:
      • MONALEESA-7
      • MONALEESA-3
      • MONARCH-2
    • The PALOMA-2 trial showed a very strong trend that has just barely missed a stringent predefined threshold of statistical significance:
      • The results, including the magnitude of benefit:
        • Are remarkably consistent across these trials

img_3760

  • Rodrigo Arrangoiz MS, MD, FACS cirujano de mama / cirujano oncology y miembro de Sociedad Quirúrgica S.C en el America British Cowdray Medical Center en la ciudad de Mexico:
    • Es experto en el manejo del cáncer de mama.

Training:

• General surgery:

• Michigan State University:

• 2004 al 2010

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• Fox Chase Cancer Center (Filadelfia):

• 2010 al 2012

• Masters in Science (Clinical research for health professionals):

• Drexel University (Filadelfia):

• 2010 al 2012

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• IFHNOS / Memorial Sloan Kettering Cancer Center:

• 2014 al 2016

#Arrangoiz

#Surgeon

#Cirujano

#SurgicalOncologist

#CirujanoOncologo

#BreastSurgeon

#CirujanodeMama

#CancerSurgeon

#CirujanodeCancer

http://www.sociedadquirurigca.com

Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment